Why the study?
Does 3,4-diaminopyridine improve fatigue in patients with multiple sclerosis?
Population
8 patients with multiple sclerosis and troublesome fatigue
Comparison
3,4-diaminopyridine (25-60 mg/day) for 3 weeks vs Baseline (before treatment)
Design
Cohort, open-labelled
Follow-up
3 weeks
Authors
Loading...
May support symptomatic MS fatigue relief; hypothesis-generating and requires RCTs before any practice change.
Does 3,4-diaminopyridine improve fatigue in patients with multiple sclerosis?
3,4-diaminopyridine may provide symptomatic improvement of fatigue in multiple sclerosis, though objective electrophysiological changes are minimal.
G. Sheean (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: